INVITROGEN CORP Form 8-K June 12, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 12, 2008

Invitrogen Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of

000-25317 (Commission File Number) 33-0373077 (IRS Employer

incorporation) Identification No.)

5791 Van Allen Way, Carlsbad, CA
(Address of principal executive offices)

Registrant s telephone number, including area code: (760) 603-7200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- x Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 Other Events

Item 8.01. Other Events.

On June 12, 2008, Invitrogen Corporation, or the Company, and Applera Corporation, or Applera, issued a press release announcing the entry into a definitive agreement to merge Applera with and into Atom Acquisition, LLC, a direct wholly owned subsidiary of the Company, or Atom Acquisition. Atom Acquisition will be the surviving corporation and the Company s wholly owned subsidiary. A copy of the press release issued by the Company and Applera on June 12, 2008 regarding the transaction is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Section 9 Financial Statements and Exhibits

Item 9.01 Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release, dated June 12, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVITROGEN CORPORATION

(Registrant)

By: /s/ John A. Cottingham John A. Cottingham

General Counsel

Date: June 12, 2008